Kepler Cheuvreux Suisse SA Makes New $2.73 Million Investment in Abbott Laboratories $ABT

Kepler Cheuvreux Suisse SA purchased a new position in shares of Abbott Laboratories (NYSE:ABT) during the fourth quarter, HoldingsChannel reports. The firm purchased 21,810 shares of the healthcare product maker’s stock, valued at approximately $2,733,000.

A number of other institutional investors have also recently bought and sold shares of the business. Harbor Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $27,000. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories during the third quarter worth approximately $31,000. Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter worth approximately $33,000. Finally, Copia Wealth Management bought a new stake in shares of Abbott Laboratories during the third quarter worth approximately $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Medical Devices segment delivered 8.5% Q1 growth, with electrophysiology, rhythm management, and heart failure products driving gains. That reinforces the company’s long-term growth story and suggests its device portfolio remains a key catalyst for ABT. Abbott’s Medical Device Strategy Supports Long-Term Growth Outlook
• Positive Sentiment: Wall Street analysts remain bullish on Abbott Laboratories despite its recent underperformance versus the broader market, which can help cushion sentiment around the stock. Abbott Laboratories Stock: Analyst Estimates & Ratings
• Positive Sentiment: Wells Fargo reaffirmed its Buy rating on ABT, adding to the view that analysts still see upside potential despite near-term weakness. Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
• Neutral Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for Abbott to $5.47 from $5.48, which is only a minor change and close to consensus, so the impact looks limited. Abbott Laboratories news item referencing Erste Group Bank estimate reduction
• Negative Sentiment: ABT has underperformed over the past year, and recent share-price weakness has kept investors focused on whether the stock is now cheap rather than on a strong near-term rebound. Is Abbott Laboratories (ABT) Now Offering Value After Recent Share Price Weakness?

Abbott Laboratories Trading Down 0.1%

Shares of ABT stock opened at $84.24 on Monday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a market cap of $146.72 billion, a P/E ratio of 23.60, a price-to-earnings-growth ratio of 1.41 and a beta of 0.65. The stock has a 50 day simple moving average of $102.69 and a 200 day simple moving average of $115.09. Abbott Laboratories has a 1 year low of $84.08 and a 1 year high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 3.0%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Activity

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction on Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. reduced their price objective on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Bank of America reduced their price objective on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Mizuho reduced their price objective on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a report on Friday, April 17th. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Finally, Weiss Ratings cut Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.43.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.